Updated Perinatal Treatment Guidelines Now Available!

The Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States has been updated and restructured into principles for management of the woman and her infant during the antepartum, intrapartum, and postpartum period, including panel recommendations for each section. Changes to the report include:

• Due to contamination with ethyl methane sulfonate (EMS), nelfinavir is no longer recommended for use in pregnant HIV-infected women
• New sections on antepartum management of HIV-infected pregnant women in special situations, including HBV and HCV coinfection 
• New information on ARV drug choice and continuation during labor, and management of women not receiving antepartum ARVs
• New sections on choice and management of infant ARV prophylaxis 
• Two new tables: "Results of Major Studies on ARV Prophylaxis to Prevent Mother-to-Child HIV Transmission" and "Clinical Scenario Summary Recommendations for ARV Use by Pregnant HIV-Infected Women and Prevention of Perinatal HIV-1Transmission in the U.S."
• Updated information for emtricitabine, tenofovir, amprenavir, atazanavir, lopinavir/ritonavir, nelfinavir, maraviroc, and raltegravir in Table 2, "Preclinical & Clinical Data Relevant to the Use of ARVs in Pregnancy"
• Updated information for tenofovir, saquinavir-HGC, atazanavir, nelfinavir, maraviroc, and raltegravir in Table 3, "ARV Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy"

The updated guidelines are available for download from the Perinatal Guidelines section of the AIDSinfo Web site. You can also request to receive them by mail or e-mail from the AIDSinfo Order Publications section.

Your feedback is important!

The Perinatal HIV Guidelines Working Group would like to hear your feedback on the latest revisions to the Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Please send your comments with the subject line "Perinatal Comments" to AIDSinfoWebmaster@aidsinfo.nih.gov by November 16, 2007.

---

AIDSinfo Launches Redesigned Home Page!

AIDSinfo has redesigned its home page! The new home page has been updated with a more visually dynamic interface while maintaining the feel and features that AIDSinfo visitors are accustomed to.

Check it out!

---